Posted: 13 October 2023
Optiscan Imaging Limited (ASX: OIL) is pleased to advise a number of key leadership appointments as it pursues further growth and expansion of its subsidiary, Optiscan Imaging, Inc. in the United States.
The Company is delighted to announce that Tim Rowe and Shayra Leon have been appointed to the respective positions of Business Development Manager (North America East Coast) and Business Development Manager (North America West Coast).
Mr Rowe joins Optiscan from Horiba Scientific Inc. where he was working as Regional Sales Manager for Fluorescence/Raman Spectroscopy/Custom Optical Spectroscopy, and previously as Senior Sales Engineer at PerkinElmer Health Sciences. Tim brings more than 15 years of experience in sales and business development in life sciences imaging to the Company. Commencing 10 October 2023, Mr. Rowe will initially be responsible for the growth of ViewnVivo® and the Company’s life sciences business throughout the US and Canada with a focus on the East Coast.
Ms Leon joins Optiscan from Lumencor where she was working as Global Business Development Manager, and previously as a Sales Executive – Pathology at Leica Biosystems. Shayra brings more than 15 years of experience in sales and business development in pathology and imaging systems to the Company. Commencing 10 October 2023, Ms. Leon will initially be responsible for the growth of ViewnVivo® and the Company’s life sciences business throughout the US and Canada with a focus on the West Coast.
Optiscan CEO and Managing Director Dr Camile Farah, stated, “These appointments reflect significant structuring and resourcing of our organisation in the US. Following an extensive search for exceptional talent, we are delighted to welcome Tim and Shayra to our team. Their experience will be extremely valuable as we strategically pursue the Company’s commercial interests in the US. Their appointments signal the first stage of talent acquisition for our US operational structure, and we look forward to further expanding the team as our plans for US collaboration and commercialization continue.”
Dr Camile Farah, continued, “The US market is strategically significant as we pursue recurring revenue generation. The inception of Optiscan Imaging Inc., a wholly owned subsidiary of the Company, and recruitment of high calibre personnel marks a new era of rapid growth and commercial success. I look forward to sharing further updates on key success and milestones in future.”
Optiscan’s Non-Executive Chairman, Mr Robert Cooke added, “The decision to implement a direct market business model underscores a significant and intricate undertaking by Dr. Farah and his team, which already encompasses jurisdictional responsibilities, taxation obligations and a commercial hub in Minnesota. The Board looks forward to supporting and furthering Dr. Farah’s strategic vision for Optiscan Imaging Inc. in the United States.”
